|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 101 Constitution Avenue, NW |
Address2 | Suite 600 West |
City | Washington |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 39837-1005573
|
||||||||
|
6. House ID# 328020678
|
TYPE OF REPORT | 8. Year | 2016 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Edward Long, PhD, Vice President |
Date | 7/19/2016 6:40:42 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
S.3040, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations, FY2017, provisions relating to NIH and drug abuse and treatment
H.R.5293/S.3000, Department of Defense Appropriations, FY2017, provisions relating to drug abuse
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Edward |
Long, PhD |
|
|
|
Katherine |
Vanlandingham |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
H.R.5293/S.3000, Department of Defense Appropriations, FY2017, provisions relating to drug abuse
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Edward |
Long, PhD |
|
|
|
Katherine |
Vanlandingham |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
S.3040, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations, FY2017, provisions relating to NIH and drug abuse and treatment
H.R.6, 21st Century Cures Act, Medical research issues.
Drug abuse research and treatment related issues:
S. 2030, The Advancing Targeted Therapies for Rare Diseases Act of 2015
S. 1622, The FDA Device Accountability Act of 2015
S. 2014, Next Generation Researchers Act
S. 800, The Enhancing the Stature and Visibility of Medical Rehabilitation Research at NIH Act
S. 849, Advancing Research for Neurological Diseases Act of 2015
S. 2503, Preventing Superbugs and Protecting Patients Act
S. 2511, Improving Health Information Technology
S. 1878, The Advancing Hope Act of 2015
S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015
S. 1101, The Medical Electronic Data Technology Enhancement for Consumers Health Act
S. 2055, The Medical Countermeasures Innovation Act of 2015
S. 1767, The Combination Products Innovation Act of 2015
S. 1597, Patient Focused Impact Assessment Act of 2015
S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act
S. 2700, FDA and NIH Workforce Authorities Modernization Act
S. 185, Promise for Antibiotics and Therapeutics for Health Act
S. 2713, Advancing Precision Medicine Act of 2016
S. 2745, Advancing NIH Strategic Planning and Representation in Medical Research Act
S. 2742, Promoting Biomedical Research and Public Health for Patients Act
Opioid abuse legislation.
H.R.2872, Opioid Addiction Treatment Modernization Act
H.R.3537, Synthetic Drug Control Act of 2015
H.R.2536/S.1455, Recovery Enhancement for Addiction Treatment Act TREAT Act
H.R.2805, Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015
H.R.3014, Medical Controlled Substances Transportation Act of 2015
H.R.3716, Ensuring Terminated Providers are Removed from Medicaid and CHIP Act
H.R.3821, Medicaid DOC Act
H.R.2646, Helping Families in Mental Health Crisis Act of 2015
S.524, Comprehensive Addiction and Recovery Act of 2016
H.R.4396, Heroin and Prescription Drug Abuse Prevention and Reduction Act
S.2256, Co-Prescribing Saves Lives Act of 2015
S.480, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015
S.2680, Mental Health Reform Act of 2016
S.2687, Plan of Safe Care Improvement Act
S.2423/H.R.4447, Opioid and Heroin Epidemic Emergency Supplemental Appropriations Act
S.1455/H.R.2536, Recovery Enhancement for Addiction Treatment Act (TREAT Act)
H.R.5046, Comprehensive Opioid Abuse Reduction Act of 2016
H.R.3680, Co-Prescribing to Reduce Overdoses Act of 2016
H.R.4981, Opioid Use Disorder Treatment Expansion and Modernization Act
H.R.3691, Improving Treatment for Pregnant and Postpartum Women Act of 2016
H.R.4586, Lali's Law
H.R.4976, Opioid Review Modernization Act of 2016
H.R.4599, Reducing Unused Medications Act of 2016
H.R.4969, John Thomas Decker Act of 2016
H.R.4641, To provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes.
H.R.4978, NAS Healthy Babies Act
H.R.3691, Improving Treatment for Pregnant and Postpartum Women Act of 2016
H.R.4229/S.36, Protecting Our Youth from Dangerous Synthetic Drugs Act of 2015
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Edward |
Long, PhD |
|
|
|
Katherine |
Vanlandingham |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |